Zhu Zhiyun,Wang Huanmin,Wang Jiarong,et al.Initial observations of hyperthermic intraperitoneal chemotherapy for pediatric abdominal cancer[J].Journal of Clinical Pediatric Surgery,2022,21(12):1116-1122.[doi:10.3760/cma.j.cn101785-202202024-004]
腹腔热灌注化疗在儿童腹部恶性肿瘤手术中的应用研究
- Title:
- Initial observations of hyperthermic intraperitoneal chemotherapy for pediatric abdominal cancer
- Keywords:
- Abdominal Neoplasms; Hyperthermic Intraperitoneal Chemotherapy; Surgical Procedures; Operative; Treatment Outcome; Child
- 摘要:
- 目的 探讨腹腔热灌注化疗(hyperthermic intraperitoneal chemotherapy,HIPEC)应用于儿童腹部恶性肿瘤的安全性、可行性及初步疗效。方法 回顾性分析首都医科大学附属北京儿童医院肿瘤外科和保定市儿童医院肿瘤外科2019年12月至2021年5月收治的16例腹部恶性肿瘤患儿临床资料,16例患儿中位年龄5岁8个月(8个月至13岁11个月),均行手术切除(细胞减灭术或肿瘤切除术),同时术中行HIPEC。收集所有患儿临床特点、治疗过程及初步疗效。结果 16例患儿中,肾母细胞瘤5例,横纹肌肉瘤4例,肾恶性横纹肌样瘤1例,未分化肉瘤1例,未成熟畸胎瘤1例,神经母细胞瘤2例,腹膜浆液性癌1例,卵巢恶性生殖细胞肿瘤1例。本次手术为初次肿瘤切除术者6例,既往曾行肿瘤切除术、本次为肿瘤复发再手术10例。16例中位腹膜癌指数(peritoneal carcinomatosis index,PCI)评分2.5分(0~21分),肿瘤切除后细胞减灭程度(completeness of cytoreduction,CC)评分0~1分。无一例围手术期死亡或出现危及生命的并发症。4例在HIPEC后30 d内出现三级不良事件。中位随访时间8个月(3.3~20个月)。本次手术后共6例患儿复发:3例因复发死亡;1例复发后经再次化疗、手术、放疗,现无瘤生存;2例复发后化疗,带瘤生存。其余10例均未出现复发,无瘤生存。中位无病生存期(disease-free survival,DFS)7.4个月(2~20个月)。结论 HIPEC应用于儿童安全、可行,未增加围手术期严重并发症。短期随访显示HIPEC对小儿腹部恶性肿瘤可能有效,但长期有效性还需要增加病例及随访时间进一步验证。
- Abstract:
- Objective To explore the safety,feasibility and short-term outcomes of hyperthermic intraperitoneal chemotherapy (HIPEC) for abdominal cancer in children.Methods From December 2019 to May 2021,16 patients with abdominal malignant tumor underwent surgical resection (cytoreductive surgery or tumorectomy) plus HIPEC.The median age was 68(8-167) months.Clinical characteristics,therapies and short-term outcomes were retrospectively analyzed.Results The histologic types included wilms tumor (n=5),rhabdomyosarcoma (n=4),malignant renal rhabdoid (n=1),undifferentiated sarcoma (n=1),immature teratoma (n=1),neuroblastoma (n=2),serous peritoneal carcinoma (n=1) and malignant ovarian germ cell tumor (n=1).Six cases underwent the initial operation and ten cases were re-operated for tumor recurrences.The median peritoneal carcinomatosis index (PCI) was 2.5(0-21) and the completeness of cytoreduction (CC) score (0-1) post-resection.There was no perioperative mortality or life-threatening complication.Four children had grade 3 adverse events within 30 days after surgery and HIPEC.The median follow-up period was 8(3.3-20) months.After surgery and HIPEC,six cases recurred.Three children died due to recurrence.One case had chemotherapy,surgery and radiotherapy after recurrence and survived without disease while another two cases received chemotherapy after recurrence and survived with disease.The remainders had no evidence of disease.The median disease-free survival (DFS) was 7.4(2-20) months.Conclusion HIPEC is both safe and feasible for pediatric abdominal malignant tumors.There is no onset of serious perioperative complications and adverse events are tolerable.The short-term outcomes are decent while long-term effectiveness requires more cases and extended follow-ups.
参考文献/References:
[1] Harmon RL,Sugarbaker PH.Prognostic indicators in peritoneal carcinomatosis from gastrointestinal cancer[J].Int Semin Surg Oncol,2005,2(1):3.DOI:10.1186/1477-7800-2-3.
[2] Gesche J,Beckert S,Neunhoeffer F,et al.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy:a safe treatment option for intraperitoneal rhabdomyosarcoma in children below 5 years of age[J].Pediatr Blood Cancer,2019,66(2):e27517.DOI:10.1002/pbc.27517.
[3] Hayes-Jordan A,Green H,Lin H,et al.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for children,adolescents,and young adults:the first 50 cases[J].Ann Surg Oncol,2015,22(5):1726-1732.DOI:10.1245/s10434-014-4289-y.
[4] 腹腔热灌注化疗技术临床应用专家协作组.腹腔热灌注化疗技术临床应用专家共识(2016版)[J].中华胃肠外科杂志,2016,19(2):121-125.DOI:10.3760/cma.j.issn.1671-0274.2016.02.001.Clinical Application Group of Hyperthermic Intraperitoneal Chemotherapy:Consensus on Clinical Application of Hyperthermic Intraperitoneal Chemotherapy (Edition 2016)[J].Chin J Gastrointest Surg,2016,19(2):121-125.DOI:10.3760/cma.j.issn.1671-0274.2016.02.001.
[5] 于洋,李鑫宝,林育林,等.肿瘤细胞减灭术联合腹腔热灌注化疗治疗腹膜癌1384例疗效分析[J].中华胃肠外科杂志,2021,24(3):230-239.DOI:10.3760/cma.j.cn.441530-20201110-00603.Yu Y,Li XB,Lin YL,et al.Efficacy of cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis:a report of 1384 cases[J].Chin J Gastrointest Surg,2021,24(3):230-239.DOI:10.3760/cma.j.cn.441530-20201110-00603.
[6] Huh WW,Fitzgerald NE,Mahajan A,et al.Peritoneal sarcomatosis in pediatric malignancies[J].Pediatr Blood Cancer,2013,60(1):12-17.DOI:10.1002/pbc.24293.
[7] Hayes-Jordan A,Lopez C,Green HL,et al.Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric ovarian tumors:a novel treatment approach[J].Pediatr Surg Int,2016,32(1):71-73.DOI:10.1007/s00383-015-3814-9.
[8] Guerrero WL,Munene G,Dickson PV,et al.Early experience with cytoreduction and hyperthermic intraperitoneal chemotherapy at a newly developed center for peritoneal malignancy[J].J Gastrointest Oncol,2018,9(2):338-347.DOI:10.21037/jgo.2018.01.02.
[9] Spratt JS,Adcock RA,Muskovin M,et al.Clinical delivery system for intraperitoneal hyperthermic chemotherapy[J].Cancer Res,1980,40(2):256-260.
[10] 李雁,周云峰,梁寒,等.细胞减灭术加腹腔热灌注化疗治疗腹膜表面肿瘤的专家共识[J].中国肿瘤临床,2015,42(4):198-206.DOI:10.3969/j.issn.1000-8179.20150013.Li Y,Zhou YF,Liang H,et al.Expert consensus on cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for tumors on the surface of peritoneum[J].Chin J Clin Oncol,2015,42(4):198-206.DOI:10.3969/j.issn.1000-8179.20150013.
[11] 李民驹,黄勇,刘伟光.小儿晚期恶性实体瘤的综合治疗[C]//国际小儿肿瘤研讨会暨第四届全国小儿肿瘤学术会议论文集,重庆,2003.天津:中国抗癌协会,2003:73-76.Li MJ,Huang Y,Liu WG.Comprehensive treatment of advanced malignant solid tumor in children[C]//International Symposium on Pediatric Cancer and Proceedings of the Fourth National Pediatric Cancer Academic Conference,Chongqing,2003.Tianjin:China Anti-Cancer Association,2003:73-76.
[12] Hayes-Jordan A,Anderson P,Curley S,et al.Continuous hyperthermic peritoneal perfusion for desmoplastic small round cell tumor[J].J Pediatr Surg,2007,42(8):E29-E32.DOI:10.1016/j.jpedsurg.2007.05.047.
[13] Hayes-Jordan A,Green H,Ludwig J,et al.Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis:early experience and phase 1 results[J].Pediatr Blood Cancer,2012,59(2):395-397.DOI:10.1002/pbc.24160.
[14] Scalabre A,Philippe-Chomette P,Passot G,et al.Cytoreductive surgery and hyperthermic intraperitoneal perfusion with chemotherapy in children with peritoneal tumor spread:a French nationwide study over 14 years[J].Pediatr Blood Cancer,2018,65(4):e26934.DOI:10.1002/pbc.26934.
[15] Winer L,Macedo FI,Alfawaz A,et al.Novel therapy for pediatric angiosarcoma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy[J].J Pediatr Hematol Oncol,2018,40(8):e505-e510.DOI:10.1097/MPH.0000000000001231.
[16] Reingruber B,Boettcher MI,Klein P,et al.Hyperthermic intraperitoneal chemoperfusion is an option for treatment of peritoneal carcinomatosis in children[J].J Pediatr Surg,2007,42(9):E17-E21.DOI:10.1016/j.jpedsurg.2007.06.009.
[17] Bautista F,Elias D,Pasqualini C,et al.Hyperthermic intraperitoneal chemotherapy after cytoreductive surgery for the treatment of peritoneal carcinomatosis in pediatric solid malignancies:a single institution experience[J].J Pediatr Surg,2014,49(8):1276-1279.DOI:10.1016/j.jpedsurg.2014.01.054.
[18] Hayes-Jordan A,Green H,Fitzgerald N,et al.Novel treatment for desmoplastic small round cell tumor:hyperthermic intraperitoneal perfusion[J].J Pediatr Surg,2010,45(5):1000-1006.DOI:10.1016/j.jpedsurg.2010.02.034.
[19] Hayes-Jordan AA,Coakley BA,Green HL,et al.Desmoplastic small round cell tumor treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy:results of a phase 2 trial[J].Ann Surg Oncol,2018,25(4):872-877.DOI:10.1245/s10434-018-6333-9.
[20] Sorrentino L,Serra F,Cabry F,et al.Cytoreductive surgery and HIPEC in a 14 years old patient with peritoneal recurrence of adenocarcinoma of the right colon[J].Int J Surg Case Rep,2019,57:118-121.DOI:10.1016/j.ijscr.2019.02.046.
[21] Piso P,Nedelcut SD,Rau B,et al.Morbidity and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy:data from the DGAV StuDoQ registry with 2149 consecutive patients[J].Ann Surg Oncol,2019,26(1):148-154.DOI:10.1245/s10434-018-6992-6.
[22] Hayes-Jordan A,Green HL,Lin H,et al.Complete cytoreduction and HIPEC improves survival in desmoplastic small round cell tumor[J].Ann Surg Oncol,2014,21(1):220-224.DOI:10.1245/s10434-013-3269-y.
[23] 谢晨捷,顾松,田瑞成,等.儿童复发肾母细胞瘤的治疗及预后相关因素分析[J].临床小儿外科杂志,2021,20(5):430-436.DOI:10.12260/Icxewkzz.2021.05.007.Xie CJ,Gu S,Tian RC,et al.Treatments and prognostic factors of recurrent Wilm’s tumor in children[J].J Clin Ped Sur,2021,20(5):430-436.DOI:10.12260/Icxewkzz.2021.05.007.
[24] 姚伟,董岿然,李凯,等.肝肿瘤切除术治疗POST-TEXTⅢ期和Ⅳ期肝母细胞瘤的中长期疗效分析[J].临床小儿外科杂志,2020,19(5):386-391.DOI:10.3969/j.issn.1671-6353.2020.05.003.Yao W,Dong KR,Li K,et al.Efficacies of extended hepatic resection for POST-TEXT Ⅲ/Ⅳ hepatoblastoma[J].J Clin Ped Sur,2020,19(5):386-391.DOI:10.3969/j.issn.1671-6353.2020.05.003.
[25] 中国抗癌协会腹膜肿瘤专业委员会,广东省抗癌协会肿瘤热疗专业委员会.中国腹腔热灌注化疗技术临床应用专家共识(2019版)[J].中华医学杂志,2020,100(2):89-96.DOI:10.3760/cma.j.issn.0376-2491.2020.02.003.Peritoneal Tumor Committee,Chinese Anti-Cancer Association,Hyperthermia Committee of Guangdong Anti-cancer Association:Consensus on Clinical Application of Hyperthermic Intraperitoneal Chemotherapy in China (Edition 2019)[J].Natl Med J China,2020,100(2):89-96.DOI:10.3760/cma.j.issn.0376-2491.2020.02.003.
备注/Memo
收稿日期:2022-2-10。
基金项目:中国工程院咨询研究项目(2019-XY -34)
通讯作者:孟德光,Email:m15533222221@163.com